Clinical trials in Donostia / San Sebastian

210 clinical trials in Donostia / San Sebastian, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Donostia / San Sebastian at a glance

210

clinical trials

Research sites2

Quick filters

210 trials in Donostia / San Sebastian

Open in trial search

Colorectal cancer metastatic

Recruiting

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Summit Therapeutics Inc.

Contact Research Centre

Acute myocardial infarction

Recruiting

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Selatogrel
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Sargramostim
Sponsor:Greenwich LifeSciences Inc.

Contact Research Centre

Neoplasm malignant

Recruiting

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Favezelimab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Plasma cell myeloma

Recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:BeOne Medicines I GmbH

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Myasthenia gravis

Recruiting

AUR200 for Patients with Generalized Myasthenia Gravis

Registered drug

AUR200 for Patients with Generalized Myasthenia Gravis

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:AUR200

Contact Research Centre

Myotonic dystrophy

Recruiting

A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

Registered drug

A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

Registered drug

Spain

Participants:0–17 years · 18–64 years
Substances:Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide
Sponsor:Dyne Therapeutics Inc.

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Donostia / San Sebastian

What the registry says about research in the country

01 Neurodegenerative Diseases

Groundbreaking research focusing on Parkinson's disease and Alzheimer's disease, including studies of novel therapeutics and disease-modifying treatments.

LRRK2-driven Parkinson's treatment evaluation
Early-stage Alzheimer's interventions
Down syndrome-associated Alzheimer's research

Multiple trials investigating innovative approaches to manage disease progression and symptoms.

02 Oncology Studies

Comprehensive research into various cancer types, with emphasis on advanced colorectal cancer and melanoma treatments.

Targeted therapies for pancreatic adenocarcinoma
Brain metastases in melanoma patients
Innovative combinations for lymphomas

Focus on personalized treatment approaches and novel drug combinations.

03 Rare Diseases

Specialized research targeting Amyotrophic Lateral Sclerosis (ALS) and other rare conditions, exploring innovative therapeutic approaches.

Combined therapy approaches for ALS
Soft tissue sarcoma treatments
Ocular Myasthenia Gravis studies

Development of targeted therapies for challenging medical conditions.

Back to Spain All countries